Freenome (FRNM) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
29 Aug, 2026Executive summary
Formed as a blank check company in March 2024 to pursue a business combination; no operating revenues to date, only interest income from trust investments.
Completed IPO on June 13, 2024, raising $86.25 million from 8,625,000 Class A shares, including full over-allotment exercise.
Net income for Q2 2025 was $754,847, driven by interest income; six-month net income was $1,433,402.
Financial highlights
As of June 30, 2025, total assets were $91.4 million, including $89.9 million in the Trust Account and $1.34 million in cash.
General and administrative expenses for Q2 2025 were $193,196; for six months, $449,154.
Interest income from Trust Account for Q2 2025 was $948,922; for six months, $1,910,834.
Accumulated deficit as of June 30, 2025, was $2,265,520.
$600,000 of interest income withdrawn from Trust Account for working capital in the first half of 2025.
Outlook and guidance
Intends to use trust funds to complete a business combination by June 13, 2026; failure to do so will result in liquidation.
Management believes current funds are sufficient for at least one year, but substantial doubt exists about ability to continue as a going concern if no business combination is completed.
Latest events from Freenome
- IPO filing details a well-funded, AI-driven cancer screening innovator with FDA approval and major partnerships.FRNM
Registration filing - SPAC raised $86.25M, reports $1.91M net income, must acquire or liquidate in 24 months.FRNM
Q4 2024 - SPAC holds $91.9M in trust, targets Freenome merger in 2026, but faces going concern risks.FRNM
Q4 2025 - Vote sought to extend business combination deadline by one year, with redemption rights offered.FRNM
Proxy filing - Q1 2025 net income reached $678,555, with $90.6M in assets and ongoing exposure to global market risks.FRNM
Q1 2025 - Q1 2026 saw a net loss and rising expenses as the company pursues the Freenome merger.FRNM
Q1 2026 - Vote sought to extend merger deadline by one year; redemption rights and board support highlighted.FRNM
Proxy filing - Q3 net income reached $981,482, with all proceeds held in trust pending a business combination.FRNM
Q3 2024 - IPO completed, $86.25M raised; Q2 net income $102,875; business combination targeted by June 2026.FRNM
Q2 2024